Raffles Family Office (RFO) Thursday said it bought a stake in a privately held Hong Kong biotechnology company that works in the field of the early detection and management of cancer. The investment, part of the Cellomics’ series B funding round, was led by RFO, and follows earlier rounds backed by strategic investors, including Hong Kong-listed Jacobson Pharma and Shenzhen-listed…
Have a confidential tip? Get in touch [email protected]